Logo image of ADPT

ADAPTIVE BIOTECHNOLOGIES (ADPT) Stock Fundamental Analysis

USA - NASDAQ:ADPT - US00650F1093 - Common Stock

14.14 USD
-0.36 (-2.48%)
Last: 11/13/2025, 8:13:56 PM
14.14 USD
0 (0%)
After Hours: 11/13/2025, 8:13:56 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ADPT. ADPT was compared to 58 industry peers in the Life Sciences Tools & Services industry. ADPT may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, ADPT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ADPT has reported negative net income.
In the past year ADPT has reported a negative cash flow from operations.
In the past 5 years ADPT always reported negative net income.
ADPT had a negative operating cash flow in each of the past 5 years.
ADPT Yearly Net Income VS EBIT VS OCF VS FCFADPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

1.2 Ratios

The Return On Assets of ADPT (-24.55%) is worse than 70.69% of its industry peers.
The Return On Equity of ADPT (-67.78%) is worse than 74.14% of its industry peers.
Industry RankSector Rank
ROA -24.55%
ROE -67.78%
ROIC N/A
ROA(3y)-28.97%
ROA(5y)-24.49%
ROE(3y)-64.83%
ROE(5y)-49.7%
ROIC(3y)N/A
ROIC(5y)N/A
ADPT Yearly ROA, ROE, ROICADPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

Looking at the Gross Margin, with a value of 66.04%, ADPT belongs to the top of the industry, outperforming 87.93% of the companies in the same industry.
In the last couple of years the Gross Margin of ADPT has declined.
ADPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 66.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.26%
GM growth 5Y-4.14%
ADPT Yearly Profit, Operating, Gross MarginsADPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

ADPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ADPT has more shares outstanding
The number of shares outstanding for ADPT has been increased compared to 5 years ago.
The debt/assets ratio for ADPT is higher compared to a year ago.
ADPT Yearly Shares OutstandingADPT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
ADPT Yearly Total Debt VS Total AssetsADPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of 0.26, we must say that ADPT is in the distress zone and has some risk of bankruptcy.
ADPT has a Altman-Z score of 0.26. This is in the lower half of the industry: ADPT underperforms 70.69% of its industry peers.
A Debt/Equity ratio of 0.72 indicates that ADPT is somewhat dependend on debt financing.
ADPT's Debt to Equity ratio of 0.72 is on the low side compared to the rest of the industry. ADPT is outperformed by 75.86% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.72
Debt/FCF N/A
Altman-Z 0.26
ROIC/WACCN/A
WACC10.24%
ADPT Yearly LT Debt VS Equity VS FCFADPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 2.85 indicates that ADPT has no problem at all paying its short term obligations.
ADPT has a Current ratio (2.85) which is in line with its industry peers.
ADPT has a Quick Ratio of 2.76. This indicates that ADPT is financially healthy and has no problem in meeting its short term obligations.
ADPT has a Quick ratio (2.76) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.85
Quick Ratio 2.76
ADPT Yearly Current Assets VS Current LiabilitesADPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 53.45% over the past year.
Looking at the last year, ADPT shows a small growth in Revenue. The Revenue has grown by 5.10% in the last year.
Measured over the past years, ADPT shows a quite strong growth in Revenue. The Revenue has been growing by 16.03% on average per year.
EPS 1Y (TTM)53.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%127.27%
Revenue 1Y (TTM)5.1%
Revenue growth 3Y5.07%
Revenue growth 5Y16.03%
Sales Q2Q%102.38%

3.2 Future

ADPT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.63% yearly.
Based on estimates for the next years, ADPT will show a very strong growth in Revenue. The Revenue will grow by 21.53% on average per year.
EPS Next Y36.48%
EPS Next 2Y19.45%
EPS Next 3Y18.14%
EPS Next 5Y12.63%
Revenue Next Year34.73%
Revenue Next 2Y23.01%
Revenue Next 3Y22.83%
Revenue Next 5Y21.53%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ADPT Yearly Revenue VS EstimatesADPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
ADPT Yearly EPS VS EstimatesADPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ADPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADPT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADPT Price Earnings VS Forward Price EarningsADPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADPT Per share dataADPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as ADPT's earnings are expected to grow with 18.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.45%
EPS Next 3Y18.14%

More info and screens

0

5. Dividend

5.1 Amount

ADPT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADAPTIVE BIOTECHNOLOGIES

NASDAQ:ADPT (11/13/2025, 8:13:56 PM)

After market: 14.14 0 (0%)

14.14

-0.36 (-2.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)02-09 2026-02-09/amc
Inst Owners97.95%
Inst Owner Change-0.09%
Ins Owners2.62%
Ins Owner Change0.04%
Market Cap2.15B
Revenue(TTM)178.96M
Net Income(TTM)-122.00M
Analysts84.29
Price Target16.76 (18.53%)
Short Float %6.09%
Short Ratio4.78
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.58%
Min EPS beat(2)30.19%
Max EPS beat(2)32.96%
EPS beat(4)4
Avg EPS beat(4)25.03%
Min EPS beat(4)12%
Max EPS beat(4)32.96%
EPS beat(8)7
Avg EPS beat(8)15.53%
EPS beat(12)10
Avg EPS beat(12)13.68%
EPS beat(16)14
Avg EPS beat(16)12.45%
Revenue beat(2)2
Avg Revenue beat(2)18.66%
Min Revenue beat(2)16.85%
Max Revenue beat(2)20.47%
Revenue beat(4)4
Avg Revenue beat(4)12.9%
Min Revenue beat(4)1.07%
Max Revenue beat(4)20.47%
Revenue beat(8)6
Avg Revenue beat(8)5.77%
Revenue beat(12)8
Avg Revenue beat(12)4.15%
Revenue beat(16)12
Avg Revenue beat(16)3.67%
PT rev (1m)17.35%
PT rev (3m)35.03%
EPS NQ rev (1m)20.02%
EPS NQ rev (3m)30.77%
EPS NY rev (1m)6.47%
EPS NY rev (3m)20.03%
Revenue NQ rev (1m)9.75%
Revenue NQ rev (3m)17.13%
Revenue NY rev (1m)2.86%
Revenue NY rev (3m)9.68%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.49
P/FCF N/A
P/OCF N/A
P/B 11.96
P/tB 36.86
EV/EBITDA N/A
EPS(TTM)-0.54
EYN/A
EPS(NY)-0.62
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS1.35
BVpS1.18
TBVpS0.38
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -24.55%
ROE -67.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 66.04%
FCFM N/A
ROA(3y)-28.97%
ROA(5y)-24.49%
ROE(3y)-64.83%
ROE(5y)-49.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.26%
GM growth 5Y-4.14%
F-Score4
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.72
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.45%
Cap/Sales 1.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.85
Quick Ratio 2.76
Altman-Z 0.26
F-Score4
WACC10.24%
ROIC/WACCN/A
Cap/Depr(3y)48.34%
Cap/Depr(5y)161.38%
Cap/Sales(3y)5.77%
Cap/Sales(5y)15.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%127.27%
EPS Next Y36.48%
EPS Next 2Y19.45%
EPS Next 3Y18.14%
EPS Next 5Y12.63%
Revenue 1Y (TTM)5.1%
Revenue growth 3Y5.07%
Revenue growth 5Y16.03%
Sales Q2Q%102.38%
Revenue Next Year34.73%
Revenue Next 2Y23.01%
Revenue Next 3Y22.83%
Revenue Next 5Y21.53%
EBIT growth 1Y34.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year70.73%
EBIT Next 3Y27.91%
EBIT Next 5Y17.61%
FCF growth 1Y51.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.42%
OCF growth 3YN/A
OCF growth 5YN/A

ADAPTIVE BIOTECHNOLOGIES / ADPT FAQ

Can you provide the ChartMill fundamental rating for ADAPTIVE BIOTECHNOLOGIES?

ChartMill assigns a fundamental rating of 2 / 10 to ADPT.


What is the valuation status of ADAPTIVE BIOTECHNOLOGIES (ADPT) stock?

ChartMill assigns a valuation rating of 0 / 10 to ADAPTIVE BIOTECHNOLOGIES (ADPT). This can be considered as Overvalued.


What is the profitability of ADPT stock?

ADAPTIVE BIOTECHNOLOGIES (ADPT) has a profitability rating of 1 / 10.


How financially healthy is ADAPTIVE BIOTECHNOLOGIES?

The financial health rating of ADAPTIVE BIOTECHNOLOGIES (ADPT) is 3 / 10.


What is the expected EPS growth for ADAPTIVE BIOTECHNOLOGIES (ADPT) stock?

The Earnings per Share (EPS) of ADAPTIVE BIOTECHNOLOGIES (ADPT) is expected to grow by 36.48% in the next year.